UK markets close in 4 hours 30 minutes

Cara Therapeutics, Inc. (CARA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
12.70-0.29 (-2.23%)
At close: 4:00PM EDT
12.69 -0.01 (-0.08%)
Pre-market: 05:56AM EDT
Sign in to post a message.
  • C
    Wall Street analysts expect that Cara Therapeutics, Inc. (NASDAQ:CARA) will post $15.74 million in sales for the current fiscal quarter, Zacks reports. Four analysts have made estimates for Cara Therapeutics’ earnings. The highest sales estimate is $25.00 million and the lowest is $7.30 million. Cara Therapeutics posted sales of $9.27 million during the same quarter last year, which indicates a positive year over year growth rate of 69.8%. The business is expected to report its next quarterly earnings results on Monday, November 8th.
    On average, analysts expect that Cara Therapeutics will report full year sales of $19.22 million for the current year, with estimates ranging from $9.60 million to $26.94 million. For the next financial year, analysts anticipate that the firm will post sales of $78.88 million, with estimates ranging from $48.21 million to $102.90 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that follow Cara Therapeutics.
  • S
    Ok y’all. Not sure what’s up. This stock is trading at parity, or perhaps at a discount to its price before the FDA approval was announced. What leadership let’s it’s stock holders get beaten so badly? Where’s the love?

    I’ve held this stock for over 5 years, and still see a bit of a gain, but would really like to see the management team take a public position of support for their beleaguered stock holders.
  • L
    This is what we get after waiting years for FDA approval.
  • W
    William H.
    On Cantor call : The inclusion of IV Korsuva in the government TADAPA payment is mandated by Law. The amount VIFOR and CARA submit is between VIFOR and CARA. Based on Amgen $650 to $700 million IV korsuva should have perhaps a billion $ put in the government package to cover IV Korsuva's use. CARA and Vifor are introducing IV korsuva in Dialysis centers now---so sales should sky rocket in first quarter 2022
  • H
    Have u ever
    thank god they got fda approval recently.
    imagine where it would be if they were rejected
  • K
    The only next milestone here is pricing, CMS pricing, I think. Does someone know something that we don't ? The low volume means that people who are waiting to buy is still waiting for this info.
  • C
    $11s coming soon with no catalysts until 2022.
  • M
    I keep hearing the same thing: The management is terrible. Can someone let me know what they are supposed to do? Seriously - what biotech did a great job of getting people jazzed? I think this is the greatest place to be. The market is missing the full potential of the drug. The market has a zillion options. Its computers look at fundamentals...but struggle to see things like a dialysis patient crying because they haven't slept in weeks due to a never ending full body itch. Here are the facts. They got a drug approved...that's incredibly hard. They found a niche for that drug and sold Vifors on investing gobs of money...and setting up an instant sales force in the process so they can attack a new market. Again, go and look at Biohaven and other companies in the exact same position. Their leaders are usually science nerds who get the science right...but aren't "hucksters". Hucksters over promise and under deliver. If you own this stock you are going to see the hockey stick when the revenue begins to roll. You bought low and are going to sell extremely high. Unless you lose our nerve...and sell low. Keep your wits about you. This one adds up to a payday...but be patient. Its coming.
  • R
    is the management sitting with their thumbs up their ----- or are they making any efforts to manufacture and sell the drug that FDA approved after like a decade of effort?!
  • R
    I sent an email to investor relations asking about the tanking stock price. Don't know if they will respond. This is unacceptable. Every day in the red! Like, what the ....?!
  • C
    So for those of you unfamiliar with CARA trading patterns, they very rarely announce anything between catalysts and quarterly reports. The EMA approval is not scheduled until 1st half of 2022 and the next 2 phase 2 trial results are not due until March and June of 2022. They will have no reportable income from IV Korsuva probably until the 2nd half of 2022. At some point maybe this year but maybe early 2022 they will announce the start of phase 3 Oral AD trial which may get a small bump but will then fall back so really until the 1st half of 2022 nothing much is likely to happen and when nothing much is happening with CARA the stock price usually sinks. Forget a buyout until Oral is approved its not going to happen. So until next year barring some unforeseen event this is probably going to languish if it follows its historical pattern.
  • B
    Cara Therapeutics presents results from the KARE Phase 2 clinical trial of oral difelikefalin for the treatment of moderate-to-severe pruritus in mild-to-severe atopic dermatitis patients
    • Results were presented by Brian Kim, MD, Associate Professor of Dermatology and Co-Director of the Center for the Study of Itch and Sensory Disorders at Washington University School of Medicine, during the Late Breaking News session of the 2021 European Academy of Dermatology and Venereology (EADV) Virtual Congress on October 2, 2021.
    • The presentation summarized data from 401 subjects with AD and moderate-to-severe pruritus, who were randomized to receive oral difelikefalin at a dose of 0.25 mg, 0.5 mg or 1.0 mg, or placebo over a 12-week treatment period. Subjects with mild-to-moderate AD were included in a prespecified analysis.
    • Approximately 64% of subjects had BSA<10 and the results of this "Itch Dominant AD" subgroup were presented.
    • Although the primary endpoint, change from baseline in Itch Numerical Rating Scale score, was not met with any of the difelikefalin dose groups in the overall population, a significant improvement (p= 0.039) in itch was observed at week 12 in the combined difelikefalin dose group in subjects with BSA <10%. In this subpopulation of itch-dominant AD, significant reduction in itch with difelikefalin was evident as early as day 2. In addition, a significantly greater proportion of subjects (32% vs 19%; p<0.05) in the combined difelikefalin dose group versus placebo achieved a =4-point improvement in I-NRS at week 12 (the required regulatory primary endpoint for Phase 3 pruritus programs). Difelikefalin was well-tolerated, with most adverse events (~95%) being mild or moderate in severity. The most commonly reported adverse events included abdominal pain, nausea, dry mouth, headache, dizziness, and hypertension. In the mouse model of AD, a rapid and significant anti-pruritic effect of difelikefalin was observed independently of effects on skin inflammation.

    (CARA), (Trade)
  • C
    I sold this after the fda approval and want to buy back in if it broke 16, but wow, is this ever going to move?
  • W
    William H.
    One major catalyst that will be announced shortly is The money that the government will include for IV Korsuva in the TDAPA package. This amount is being decided by CARA and Vifor. Amgen's Parasabin a calcimimetric( not a unique drug) added $650 -$700 million two years ago. IV Korsuva a unique drug will probably have $700 million to a $ billion added to the TDAPA package for it's use in treating patients on dialysis for pruritus. Needless to say with the money available at no cost to the patient sales of IV Korsuva should ramp quickly. CARA hitting $350 million annually should move the stock price to $60 or more
  • R
    To get a presentation in a Congress that has had it's schedule planned out and published for quite a while - imo - can only be the result of positive information to be shared with medical professionals. If the results did not meet the end point then I'm of the thought they would have them presented in such a manner.
    Onward to Phase III ?

    STAMFORD, Conn., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs), today announced that results from the KARE Phase 2 clinical trial of Oral KORSUVA™ (difelikefalin tablets) for the treatment of moderate-to-severe pruritus in mild-to-severe atopic dermatitis (AD) patients will be presented in a late-breaking presentation at the European Academy of Dermatology and Venereology (EADV) 30th Anniversary Congress, held virtually from September 29-October 2, 2021.
  • D
    Nothing from conference I'm thinking possible over the counter pain meds big dollars
  • J
    Amazing the only thing that’s going to drive this stock up is REVENUE or God almighty having an itch and using Korsuva
  • C
    There is a septic tank cleaning service here in San Diego called "Little Stinkers" I think CARA should adopt that name as well.
  • p
    I guess I should have sold pre market last week when it hit 16.25................
  • J
    No insider has bought this stock in over 3 years- plenty of selling though.